Nature Communications (Jun 2022)
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
- Sandra P. D’Angelo,
- Allison L. Richards,
- Anthony P. Conley,
- Hyung Jun Woo,
- Mark A. Dickson,
- Mrinal Gounder,
- Ciara Kelly,
- Mary Louise Keohan,
- Sujana Movva,
- Katherine Thornton,
- Evan Rosenbaum,
- Ping Chi,
- Benjamin Nacev,
- Jason E. Chan,
- Emily K. Slotkin,
- Hannah Kiesler,
- Travis Adamson,
- Lilan Ling,
- Pavitra Rao,
- Shreyaskumar Patel,
- Jonathan A. Livingston,
- Samuel Singer,
- Narasimhan P. Agaram,
- Cristina R. Antonescu,
- Andrew Koff,
- Joseph P. Erinjeri,
- Sinchun Hwang,
- Li-Xuan Qin,
- Mark T. A. Donoghue,
- William D. Tap
Affiliations
- Sandra P. D’Angelo
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Allison L. Richards
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
- Anthony P. Conley
- Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
- Hyung Jun Woo
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
- Mark A. Dickson
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Mrinal Gounder
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Ciara Kelly
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Mary Louise Keohan
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Sujana Movva
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Katherine Thornton
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Evan Rosenbaum
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Ping Chi
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Benjamin Nacev
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Jason E. Chan
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Emily K. Slotkin
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center
- Hannah Kiesler
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Travis Adamson
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Lilan Ling
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
- Pavitra Rao
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
- Shreyaskumar Patel
- Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
- Jonathan A. Livingston
- Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
- Samuel Singer
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Narasimhan P. Agaram
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Cristina R. Antonescu
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Andrew Koff
- Program in Molecular Biology, Memorial Sloan Kettering Cancer
- Joseph P. Erinjeri
- Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center
- Sinchun Hwang
- Department of Radiology, Memorial Sloan Kettering Cancer Center
- Li-Xuan Qin
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center
- Mark T. A. Donoghue
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
- William D. Tap
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- DOI
- https://doi.org/10.1038/s41467-022-30874-8
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 11
Abstract
The activity of PD-1 blockade in patients with sarcoma has been modest so far. Here, the authors report the results of a pilot clinical trial to assess the efficacy and safety of bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, in combination with the PD1 blockade (nivolumab) in patients with locally advanced or metastatic high-grade sarcoma.
